Pharma BD Deal Intelligence

Watson Pharmaceuticals, Inc. / Eden Biodesign Limited

2010 · Asset Purchase · $15M · Complete

Announcement Sentiment

Strongly positive

Watson acquired Eden Biodesign as part of broader Arrow Group transactions, providing biologic manufacturing capability for generic biologicals strategy.

Key facts

Announced Jun 21, 2010
Deal value $15M
Deal type Asset Purchase
Therapeutic area Generic biologics platform
Indications Generic biologics platform
Key assets Biologics development and manufacturing services
Mechanism Biopharmaceutical CDMO

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals